DALLAS, Jan. 7, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Hemispherx Biopharma Inc. (AMEX:HEB). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The report is available at: http://www.investorsoup.com/lp/HEB
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Hemispherx Biopharma Inc. (HEB) is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's products include Ampligen and Alferon N and Injection. Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as a vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N is an indicator for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is an application under early stage development targeting influenza and viral diseases. Ampligen is an experimental drug undergoing clinical development for the treatment of CFS.
Message Board Search for HEB: http://www.boardcentral.com/boards/HEB
In the report, the analyst notes:
"Revenues from Ampligen(R) cost recovery program increased $8,000 or 47% for the quarter in 2009 with approximately the same number of patients participating in the program. HEB has no Alferon N Injection(R) product to commercially sell at this time and all revenue was generated from the Ampligen(R) cost recovery clinical treatment programs.
"HEB stated that on December 11, 2009, the Company, via its manufacturing subcontractor, in Spokane, WA, submitted comprehensive new data to the regional office of the Food and Drug Administration that HEB management believes demonstrates that certain manufacturing issues noted in earlier pre-approval inspections at the facility have been fully addressed. The referenced reports on Ampligen(R) (Poly I: Poly C12U), an experimental therapeutic being developed for potential treatment of Chronic Fatigue Syndrome, are the combined work-product of the staffs at HEB and its subcontractor."
To read the entire report visit: http://www.investorsoup.com/lp/HEB
See what investors are saying about HEB at penny stock forum.
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.